Seer, Inc.
Redwood City, CA
- UEI
- ZJTLN42M9X85
- CAGE
- 85P21
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 3800 Bridge Pkwy #102, Redwood City, CA 94065, USA
- Website
- seer.bio
- Founded
- 2017
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $56,000 |
| FY2025 | $0 |
| FY2024 | $1,146,697 |
| FY2023 | $299,999 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $56,000 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Rapid profiling of the plasma proteome and machine learning analytics for non-invasive diagnosis of alzheimer's disease | National Institute on Aging (NIH) | $2,041,016 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Alamar Biosciecnes, Inc. | Fremont, CA | 334516 Analytical Laboratory Instrument Manufacturing |
| Proteinsimple | San Jose, CA | 334516 Analytical Laboratory Instrument Manufacturing |
| CM Life Sciences II Inc. | Boulder, CO | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Olink Proteomics Inc. | Waltham, MA | 541380 Testing Laboratories and Services |
| Takara Bio Usa, Inc. | San Jose, CA | 325414 Biological Product (except Diagnostic) Manufacturing |
About the company
Seer, Inc., operating as Seer, is a for-profit manufacturer of proteomics research equipment and services based in Redwood City, California, that works exclusively as a prime contractor on small federal purchase orders across the National Institutes of Health with no set-aside designations and no subcontract footprint. The company does not hold parent contract vehicles, IDIQs, or GWACs; all federal work flows through direct purchase orders from individual NIH institutes.
Seer's capability portfolio centers on advanced liquid chromatography-mass spectrometry (LC-MS), deep proteomic profiling using its proprietary Proteograph platform, peptide fractionation, protein corona analysis, and sample processing for biomarker discovery in aging and neurodegenerative disease research. The company's federal work is concentrated in support of gerontology and ophthalmology research — representative recent contracts include a $1,017,317 firm fixed-price purchase order from the National Institute on Aging for deep proteomic profiling of aging samples using the Proteograph platform (awarded September 2024, performance completed December 2024), a $299,999 NIA proof-of-principle study contract for longitudinal aging and senescence biomarker detection (awarded May 2023), and a $23,400 peptide fractionation and mass spectrometry services contract from the National Eye Institute (awarded August 2024). A single purchase order from the NIH Clinical Center ($22,000 preventative maintenance agreement, awarded July 2024) represents Seer's only recent work outside proteomics research services.
Customer concentration is entirely within the Department of Health and Human Services. The National Institute on Aging dominates Seer's federal footprint, accounting for seven of ten awards and the full $1.5 million in combined potential value across the portfolio. The National Eye Institute holds two awards worth $37,000 combined, and the NIH Clinical Center holds one. Notably, actual obligation dollars ($3.6 million) exceed combined potential value by 234 percent, indicating that Seer has captured follow-on work and task modifications beyond original contract ceilings on its NIA awards.
Activity accelerated sharply in 2024, with six awards placed that year compared to one award each in 2022 and 2023. The most recent award, a $56,000 LC-MS services purchase order from NIA (June 2026), carries completion through June 2027 and represents Seer's only contract with exposure in the next twenty-four months. Seer operates entirely on full-and-open, firm fixed-price purchase orders with no institutional relationship to standing contract vehicles and therefore no pipeline visibility beyond individual task orders. The vendor functions as a specialized research services vendor to NIH institutes rather than as a federal IT, engineering, or mission-support contractor; its competitive set consists of other proteomics service providers and CROs supporting NIH research grants rather than traditional federal contractors.
Quick answers
Is Seer, Inc. registered in SAM.gov?
Yes. Seer, Inc.'s SAM.gov registration is active through December 8, 2026.
How much has Seer, Inc. received in federal contracts?
Federal contracts obligated $1,502,696 to Seer, Inc. in fiscal years 2023 through 2027.
What is Seer, Inc.'s most recent federal award?
Seer, Inc.'s most recent federal contract award is NIA: service: LC MS services: severable (75N98026P00731), from Office of Logisitics and Acquisition Operations (NIH), on June 10, 2026.
On GovTribe
See Seer, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors